4.7 Article

β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs

Journal

STEM CELLS
Volume 34, Issue 6, Pages 1541-1552

Publisher

WILEY
DOI: 10.1002/stem.2335

Keywords

Pluripotent stem cells; Erythroid differentiation; Primitive and definitive hematopoiesis; Globin expression

Funding

  1. National Heart, Lung, and Blood Institute (NHLBI)
  2. National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH)

Ask authors/readers for more resources

Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells represent a potential alternative source for red blood cell transfusion. However, when using traditional methods with embryoid bodies, ES cell-derived erythroid cells predominantly express embryonic type epsilon-globin, with lesser fetal type gamma-globin and very little adult type beta-globin. Furthermore, no beta-globin expression is detected in iPS cell-derived erythroid cells. ES cell-derived sacs (ES sacs) have been recently used to generate functional platelets. Due to its unique structure, we hypothesized that ES sacs serve as hemangioblast-like progenitors capable to generate definitive erythroid cells that express beta-globin. With our ES sac-derived erythroid differentiation protocol, we obtained similar to 120 erythroid cells per single ES cell. Both primitive (E-globin expressing) and definitive (gamma- and beta-globin expressing) erythroid cells were generated from not only ES cells but also iPS cells. Primitive erythropoiesis is gradually switched to definitive erythropoiesis during prolonged ES sac maturation, concurrent with the emergence of hematopoietic progenitor cells. Primitive and definitive erythroid progenitor cells were selected on the basis of glycophorin A or CD34 expression from cells within the ES sacs before erythroid differentiation. This selection and differentiation strategy represents an important step toward the development of in vitro erythroid cell production systems from pluripotent stem cells. Further optimization to improve expansion should be required for clinical application.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available